LY6E-DT

Across TCGA pan-cancer cohorts, LY6E-DT RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of LY6E-DT’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where LY6E-DT RNA is more highly expressed in tumor relative to normal tissue. In most cancer types LY6E-DT is over-expressed in tumor, although a few such as KICH and LIHC show the opposite, repressed pattern.

KIRC, KICH, and THCA are the cancer types where LY6E-DT tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LY6E-DT RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	II,III,IV	+1.352	<.001	11	view →
KICH	Female	II,III,IV	−0.817	<.001	8	view →
THCA	All	All	+0.241	<.001	7	view →
LIHC	Female	II,III,IV	−0.704	<.001	6	view →
COAD	All	II,III,IV	+0.205	.001	6	view →
CHOL	Male	All	−0.948	<.001	5	view →
BRCA	Female	All	−0.249	.014	4	view →
ESCA	All	II,III,IV	+0.785	.014	2	view →
UCEC	All	All	−0.487	.035	2	view →
STAD	All	II,III,IV	+0.411	.010	2	view →
LUAD	Female	All	+0.335	.002	2	view →
PRAD	All	All	−0.234	<.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

LY6E-DT–KIRC

Open the KIRC breakdown →